Glucagon-like peptide-1 receptor agonists, commonly referred to as GLP-1s, are becoming increasingly widespread, with the most notable examples including Ozempic, Wegovy, and Saxenda
For beverage companies, this trend supports the incorporation of GLP-1-supporting ingredients into beverages that consumers already enjoy daily. Rachel Buss, vice president of strategic insights at Curion, Deerfield, Ill., notes that beyond off-label use, adopters have reported anecdotal changes
Frequently Asked Questions Which GLP-1 has the least side effects
Summary: GLP-1 receptor agonists produce modest reductions in total cholesterol, LDL cholesterol, and triglycerides, but are not licensed or recommended as primary treatments for dyslipidaemia
While weight loss will always be faster with medications, for overall health, dietary approaches are superior to medications